The trading price of Adma Biologics Inc (NASDAQ:ADMA) closed higher on Monday, November 18, and closing at $19.54, 2.63% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $18.9 and $19.588. The company’s P/E ratio in the trailing 12-month period was 70.72, while its 5Y monthly beta was 0.645. In examining the 52-week price action we see that the stock hit a 52-week high of $23.64 and a 52-week low of $3.60. Over the past month, the stock has gained 23.83% in value.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adma Biologics Inc, whose market valuation is $4.35 billion at the time of this writing, is expected to release its quarterly earnings report in December. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by 0.16 per share this quarter, however they have predicted annual earnings per share of 0.51 for current year and 0.73 for next year.
Analysts have forecast the company to bring in revenue of 113.4M for the current quarter, with the likely lows of 108.1M and highs of 121.2M. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 422.35M.
On the technical side, indicators suggest ADMA has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned ADMA a recommendation rating is 3. Out of them, 0 rate it a Hold, while 2 recommend Buy, whereas 1 assign an Overweight rating. 0 analyst(s) have tagged Adma Biologics Inc (ADMA) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 3.54, which symbolizes a positive outlook. A quick review shows that ADMA’s price is currently 4.67% off the SMA20 and 5.25% off the SMA50. The RSI metric on the 14-day chart is currently showing 52.83, and weekly volatility stands at 4.94%. When measured over the past 30 days, the indicator reaches 5.09%. Adma Biologics Inc (NASDAQ:ADMA)’s beta value is currently sitting at 0.67, while the Average True Range indicator is currently displaying 1.13. With analysts defining $14-$18 as the low and high price targets, we arrive at a consensus price target of $16 for the trailing 12-month period. The current price is about 28.35% off the estimated low and 7.88% off the forecast high, based on this estimate. Investors will be thrilled if ADMA’s share price rises to $16, which is the median consensus price. At that level, ADMA’s share price would be 18.12% above current price.
To see how Adma Biologics Inc stock has been performing in comparison to its peers in the industry, here are the numbers: ADMA stock’s performance was 2.63% in the latest trading, and 412.86% in the past year. Adma Biologics Inc has a P/E ratio of 70.72.
An evaluation of the daily trading volume of Adma Biologics Inc (NASDAQ:ADMA) indicates that the 3-month average is 5.16 million. However, this figure has increased over the past 10 days to an average of 4.35.
Currently, records show that 236.39 million of the company’s shares remain outstanding. The insiders hold 3.38% of outstanding shares, whereas institutions hold 89.66%. The stats also highlight that short interest as of 2024-10-31, stood at 15.2 million shares, resulting in a short ratio of 3.53 at that time. From this, we can conclude that short interest is 662.00 of the company’s total outstanding shares. It is noteworthy that short shares in October were down slightly from the previous month’s figure, which was 17.08 million. However, since the stock’s price has seen 332.30% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
